These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 6772231)
21. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time. Aihara M; Kimura A; Chiba Y; Yoshida Y Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084 [TBL] [Abstract][Full Text] [Related]
22. Role of carbohydrate in multimeric structure of factor VIII/von Willebrand factor protein. Gralnick HR; Williams SB; Rick ME Proc Natl Acad Sci U S A; 1983 May; 80(9):2771-4. PubMed ID: 6601805 [TBL] [Abstract][Full Text] [Related]
23. [Monoclonal antibodies against the factor VIII/Willebrand factor molecule: inhibition of the cofactor action of ristocetin and the antihemophilic factor]. Sola B; Avner P; Sultan Y; Jeanneau C; Maisonneuve P C R Seances Acad Sci III; 1981 May; 292(18):1055-7. PubMed ID: 6790137 [TBL] [Abstract][Full Text] [Related]
24. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. Ruggeri ZM; Zimmerman TS J Clin Invest; 1980 Jun; 65(6):1318-25. PubMed ID: 6773982 [TBL] [Abstract][Full Text] [Related]
25. Studies on factor VIII-related protein. III. Size distribution and carbohydrate content of human and bovine factor VIII. Furlan M; Perret BA; Beck EA Biochim Biophys Acta; 1979 Aug; 579(2):325-33. PubMed ID: 534647 [TBL] [Abstract][Full Text] [Related]
26. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease. Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334 [TBL] [Abstract][Full Text] [Related]
27. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. Weiss HJ; Meyer D; Rabinowitz R; Pietu G; Girma JP; Vicic WJ; Rogers J N Engl J Med; 1982 Feb; 306(6):326-33. PubMed ID: 6798442 [TBL] [Abstract][Full Text] [Related]
28. Development of an inhibitor specific to factor VIII: coagulant activity in a patient with platelet-type von Willebrand's disease. Castella A; Miller JL; Neuberg RW; Gawryl MS; Hoyer LW Am J Clin Pathol; 1983 Nov; 80(5):745-9. PubMed ID: 6416054 [TBL] [Abstract][Full Text] [Related]
29. Interaction of platelets, von Willebrand factor, and ristocetin during platelet agglutination. Moake JL; Olson JD; Troll JH; Weinger RS; Peterson DM; Cimo PL J Lab Clin Med; 1980 Jul; 96(1):168-84. PubMed ID: 6967100 [TBL] [Abstract][Full Text] [Related]
30. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. Weiss HJ; Rogers J; Brand H J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262 [TBL] [Abstract][Full Text] [Related]
31. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469 [TBL] [Abstract][Full Text] [Related]
32. Mechanism of cell entry and toxicity of an affinity- purified lectin from Ricinus communis and its differential effects on normal and virus-transformed fibroblasts. Nicolson GL; Lacorbiere M; Hunter TR Cancer Res; 1975 Jan; 35(1):144-55. PubMed ID: 162859 [TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibodies against the human factor VIII von Willebrand molecule: characterization and potential for screening of von Willebrand patients. Avner P; Arnaud D; Sultan Y; Maisonneuve P; Jeanneau C Dev Biol Stand; 1984; 57():69-76. PubMed ID: 6084622 [TBL] [Abstract][Full Text] [Related]
34. Reactivity of small molecular forms of human factor VIII/von Willebrand factor with botrocetin and anti-factor VIII-coated latex particles. Furlan M; Perret BA; Beck EA Thromb Haemost; 1985 Aug; 54(2):463-5. PubMed ID: 3936216 [TBL] [Abstract][Full Text] [Related]
35. The nature of the interaction between ristocetin-Willebrand factor VIII coagulant activity molecule. Brockway WJ; Fass DN J Lab Clin Med; 1977 Jun; 89(6):1295-1305. PubMed ID: 16975 [No Abstract] [Full Text] [Related]
36. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome. Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586 [TBL] [Abstract][Full Text] [Related]
37. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. Miller JL; Kupinski JM; Castella A; Ruggeri ZM J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113 [TBL] [Abstract][Full Text] [Related]
38. The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility. Coller BS J Clin Invest; 1978 May; 61(5):1168-75. PubMed ID: 307006 [TBL] [Abstract][Full Text] [Related]
39. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor. Turecek PL; Siekmann J; Schwarz HP Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238 [TBL] [Abstract][Full Text] [Related]
40. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. Ruggeri ZM; Pareti FI; Mannucci PM; Ciavarella N; Zimmerman TS N Engl J Med; 1980 May; 302(19):1047-51. PubMed ID: 6767976 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]